Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, McIntyre Partnerships. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD-25%
YTD-25.9%
Annualized+8.5%
Positioning StanceCONSTRUCTIVE
Market CapAll Cap
GeographyUS
Digest Analysis
Quick Take
"Extreme portfolio concentration in deeply discounted turnarounds like QuidelOrtho provides asymmetric upside as respiratory testing volumes rebound from cyclical troughs."
Executive Summary
McIntyre Partnerships experienced significant quarterly headwinds in the third quarter of 2026, delivering a net return of -25.0% net of fees, which brings year-to-date performance to -25.9% net of fees. The fund trailed its benchmark, the Russell 2000 Value, driven primarily by severe price weakness in its largest concentrated holding. The partnership maintained an aggressive portfolio posture, ending the period with exposures of 126% long and 35% short, yielding 91% net exposure, or 79% net exposure after adjustments for options and risk arbitrage. The portfolio remains highly concentrated, with the top five positions accounting for roughly 85% of total partnership assets. Macroeconomic influences remained focused on interest rate volatility and shifting sentiment across commercial drug development and healthcare tools. Rising interest rates created modest valuation headwinds for real estate-linked assets, while biotechnology research funding and life science sentiment rebounded positively following major corporate laboratory expansions. The manager views underlying operating fundamentals across core investments as resilient despite near-term mark-to-market turbulence. Portfolio results were dictated predominantly by QuidelOrtho, which fell sharply after opting not to sell its Point-of-Care division. The fund maintained its concentrated stake, citing high flu test positivity and operational cost cuts as powerful fundamental earnings drivers. Complementary holdings in Fortrea Holdings contributed positive gains amid commercial drug development tailwinds, while smaller positions in Star Holdings, Starz Entertainment, and Seaport Entertainment experienced modest volatility alongside continuous progress in underlying asset liquidations and leasing milestones.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
92%
CautiousHigh
High Conviction (92%)
Portfolio construction displays extreme conviction, with the top five holdings accounting for roughly 85% of capital and QuidelOrtho initially sized at over 20%. The manager explicitly commits to absorbing elevated drawdowns without reducing exposure until shares appreciate substantially or the thesis is disproven. High concentration is balanced by active hedging through options and risk arbitrage overlays.
Growth Outlook
55%
BearishBullish
Neutral (55%)
General market sentiment is addressed neutrally, with broader macro comparisons deemed secondary to idiosyncratic, single-stock developments. Constructive views on expanding healthcare research budgets and stabilizing clinical testing are balanced against headwinds from rising interest rates. Overall market indices are viewed as less relevant than individual asset mispricings.
Risk Appetite
85%
DefensiveAggressive
Aggressive (85%)
Positioning reflects high risk tolerance, maintaining 126% gross long exposure and a net exposure of 91% (79% net adjusted for arbitrage). Sizing a leveraged turnaround above 20% of capital during a trough earnings period demonstrates significant aggressive appetite. Capital preservation is pursued via specific corporate debt waivers rather than broad equity de-risking.
Capital Deployment
65%
De-riskingDeploying
Net Neutral (65%)
Capital remains fully committed across high-conviction longs with minimal cash holdings and substantial net long exposure. Selective profit-taking in outperformers provided rebalancing flexibility rather than an overall liquidity build. Portfolio posture demonstrates persistent deployment into deeply discounted turnaround assets.
Forward Guidance
70%
CautiousExpansionary
Expansionary (70%)
The manager clearly signals an intention to hold and potentially scale core positions through near-term volatility as fundamental operating improvements manifest. Having previously trimmed high-performing winners like STRZ, capital remains committed to high-upside recovery assets. Directional posture favors riding operational leverage rather than rotating into cash.
Language Signal
72%
BearishBullish
Bullish (72%)
Discourse centers heavily on multibagger return potential, earnings beats, operating leverage, and significant free cash flow inflection points. Negative language is largely restricted to describing backward-looking price declines, aborted divestitures, and elevated debt leverage. The tone regarding forward fundamental developments remains assertively optimistic.
Perceived Risk
45%
Low RiskElevated
Moderate Risk (45%)
Macro risk perceptions are moderate, with rising interest rates highlighted as an external factor weighing on real estate equity valuations. Systemic financial contagion is not emphasized, and industry-specific threats such as AI disruption in drug development are framed as manageable or net-positive. Primary risk recognition focuses on corporate debt covenant buffers and balance sheet leverage.
Opportunity Density
60%
ScarceAbundant
Selective (60%)
The investment set is intentionally concentrated into exceptional, rare value mispricings rather than a broad, diversified opportunity landscape. Multibagger risk/reward profiles are explicitly characterized as exceptionally rare occurrences requiring aggressive capital commitment. New idea generation appears selective, focusing deeply on five primary assets.
Time Horizon
75%
Short-TermLong-Term
Decade+ (75%)
Investment horizons span multiple years, explicitly looking ahead to financial performance and free cash flow targets in 2027 and 2028. Short-term quarterly fluctuations and price weakness driven by event-driven fund exits are intentionally overlooked in favor of multi-year operational recoveries. Patience is emphasized while awaiting tenant lease commencements and testing cycle normalizations.